company background image
NONO.F logo

Novo Nordisk OTCPK:NONO.F Stock Report

Last Price

US$130.60

Market Cap

US$580.1b

7D

-1.2%

1Y

69.1%

Updated

25 Mar, 2024

Data

Company Financials +

NONO.F Stock Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.

NONO.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance6/6
Financial Health4/6
Dividends3/6

Novo Nordisk A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Novo Nordisk
Historical stock prices
Current Share Pricekr.130.60
52 Week Highkr.140.32
52 Week Lowkr.74.70
Beta0.18
1 Month Change4.98%
3 Month Change29.71%
1 Year Change69.08%
3 Year Change277.02%
5 Year Change408.07%
Change since IPO678.87%

Recent News & Updates

Recent updates

Shareholder Returns

NONO.FUS PharmaceuticalsUS Market
7D-1.2%0.2%1.3%
1Y69.1%23.1%29.8%

Return vs Industry: NONO.F exceeded the US Pharmaceuticals industry which returned 23.6% over the past year.

Return vs Market: NONO.F exceeded the US Market which returned 30.4% over the past year.

Price Volatility

Is NONO.F's price volatile compared to industry and market?
NONO.F volatility
NONO.F Average Weekly Movement5.4%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: NONO.F has not had significant price volatility in the past 3 months.

Volatility Over Time: NONO.F's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
192363,845Lars Jorgensenhttps://www.novonordisk.com

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.

Novo Nordisk A/S Fundamentals Summary

How do Novo Nordisk's earnings and revenue compare to its market cap?
NONO.F fundamental statistics
Market capUS$580.10b
Earnings (TTM)US$12.16b
Revenue (TTM)US$33.76b

47.7x

P/E Ratio

17.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NONO.F income statement (TTM)
Revenuekr.232.26b
Cost of Revenuekr.35.77b
Gross Profitkr.196.50b
Other Expenseskr.112.81b
Earningskr.83.68b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)18.75
Gross Margin84.60%
Net Profit Margin36.03%
Debt/Equity Ratio20.0%

How did NONO.F perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

50%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.